Compare DexCom, Inc. (DXCM) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs UiPath Inc — how do they compare? DexCom, Inc. trades at $77.39 (market cap $28.06B), while UiPath Inc trades at $12 (market cap $6.19B). The key difference: DexCom, Inc. is far larger — about 4.5× UiPath Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | PATH | |
|---|---|---|
Market Cap | $28.06B | $6.19B |
Sector | Health | Technology |
52-Week High | $89.53 | $19.29 |
52-Week Low | $54.84 | $9.38 |
Enterprise Value | $27.03B | $4.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
UiPath (PATH) trades at $11.81, down 1.09% on the day, with a bullish technical signal from moving averages and oscillators. The company reported Q4 2025 EPS of $0.30, beating estimates, but missed in Q1 2026. Revenue growth is strong, reaching $1.43B in 2025, with improving net margins from -58.91% in 2022 to -5.16% in 2025. Analysts maintain a consensus price target of $13.33, suggesting upside potential. Recent news highlights agentic AI advancements with Maestro Case launches.
PATH presents a growth opportunity with robust revenue expansion and margin improvement, though profitability remains negative. Risks include execution on AI monetization and competitive pressures. The stock's current pullback may offer an attractive entry point, supported by bullish analyst sentiment and technical indicators, but investors should weigh near-term earnings volatility against long-term automation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
